Poolbeg Pharma (LON:POLB) Shares Up 12.1% – What’s Next?

Poolbeg Pharma PLC (LON:POLB) traded up 12.1% on Tuesday . The stock traded as high as GBX 6.56 and last traded at GBX 6.56. 1,736,688 shares were traded during trading, an increase of 36% from the average session volume of 1,280,718 shares. The stock had previously closed at GBX 5.85.

Analysts Set New Price Targets

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research report on Tuesday, May 26th.

Poolbeg Pharma Trading Up 12.1%

The business has a fifty day moving average of GBX 4.60 and a 200-day moving average of GBX 4.35. The firm has a market cap of £46.25 million, a PE ratio of -6.98 and a beta of 1.78.

Poolbeg Pharma (LON:POLB) last announced its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. On average, equities analysts forecast that Poolbeg Pharma PLC will post -0.68 EPS for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.